Abstract:DEAR EDITOR, Severe coronavirus disease 2019 (COVID19) is a well-recognized cause of morbidity and mortality across rheumatic diseases [1], and vaccines will play an important role in preventing illness. Immunosuppressive agents are commonly used in the treatment of rheumatological diseases, and among them, anti-CD-20 depleting therapies can result in an impaired humoral response to vaccines [2]. We had previously reported a case of COVID-19 vaccine failure in a patient on ocrelizumab therapy, an anti-CD19 mAb [3]. Here, we report another case of vaccine failure, this time in a patient on rituximab, an anti-CD20 mAb.A 73-year-old Caucasian male presented with nasal congestion, productive cough, myalgias and malaise of 4 days duration. Five weeks before, he had completed a two-dose series of the Pfizer-BioNTech COVID-19 vaccine given 21 days apart. He had a history of cryptogenic organizing pneumonia, intermittent asthma, type II diabetes mellitus, hyperlipidaemia and coronary artery disease. He was diagnosed with cryptogenic organizing pneumonia 2 years earlier, which was initially treated with prednisone and switched to rituximab owing to an inadequate treatment response. He was scheduled for i.v. rituximab infusion therapy at a dose of 375 mg/m every 6 months, and his last dose was administered 10 days after he had received the second dose of the vaccine. His medications included metoprolol succinate, atorvastatin, ezetimibe, metformin, sitagliptin, and a budesonide and formoterol inhaler. There were no known allergies. The patient is retired and lives in New York City. Since the start of the COVID-19 pandemic, he had restricted his participation in social activities and wore a face mask in public. He denied any history of alcohol, tobacco or illicit drug use. On examination, the patient appeared comfortable. Vitals signs were within normal limits. His respiratory effort and breath sounds were normal, as was the remainder of the physical examination. He tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via an RT-PCR nasopharyngeal swab. Given the high risk of progression to severe COVID-19 disease owing to his age and comorbidities, bamlanivimab and etesivimab, an mAb cocktail against SARS-CoV-2 was administered uneventfully. Serological testing was performed before the mAb cocktail infusion with two separate assays, assessing the immunological response to the spike and nucleocapsid protein of SARS-CoV-2, respectively. He tested negative for antibodies to both the spike (S) and nucleocapsid (N) antigens. He reported resolution of his symptoms 3 days after the infusion. Rituximab is an anti-CD20 mAb that binds to the CD20 antigen on the B cell surface, activating complement-dependent B cell cytotoxicity. B cells are believed to play a role in the development and progression of some autoimmune diseases. Signs and symptoms of those diseases are reduced by targeting B cells, and the progression of structural damage is delayed. Rituximab is widely used in patients with autoimmune disorders, haematological malignancies and vasculitides. The B-cell-depleting nature of rituximab therapy can lead to an impaired humoral immune response to vaccination. Studies have shown a blunted influenza vaccine response in patients on rituximab. The effect was most pronounced if vaccinated <2 months, with an improved response if vaccinated >6 months after rituximab therapy [4]. In the vaccine clinical guidance by the ACR [5], patients with a low or mitigatable risk of COVID-19 should have their vaccination scheduled 4 weeks before their next scheduled rituximab cycle; and after the completion of vaccination, should delay rituximab for 2–4 weeks after the second vaccine dose, if disease activity allows. A recent review article in Rheumatology recommended avoiding vaccination after rituximab, ideally for 6months; and if vaccination is imminent, consider delaying rituximab if there are no risks of organ failure or disease flare [6]. In our patient, rituximab was administered 10days after the last dose of the vaccine, and the patient developed clinical disease 5 weeks after completing vaccination. The absence of spike protein antibodies indicates an inadequate humoral response after 5weeks. Peak antibody response is expected 2weeks after the second dose of the COVID-19 vaccine [7]. The two-dose regimen of the vaccine confers a 95% protection against infection [8], and this could explain vaccine failure rather than use of rituximab. The half-life and prolonged B-cell-depleting effects of rituximab make it challenging to obtain an optimal window for vaccination. T-cell-mediated immunity after vaccination could have played a role in the mild nature of his illness, which was not accounted for by measuring only the humoral antibody response. Our case highlights the challenges in vaccinating patients on immunosuppressive drugs. Finding an optimal window and obtaining post-vaccination antibody titres might be beneficial. Patients should continue to maintain a high adherence to preventive measures Key message

B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19)

Timing is essential: Humoral and cellular responses to SARS-CoV-2 vaccination in a cohort of patients with auto-immune diseases treated with rituximab

Effect of Traditional Therapeutics on Prevalence and Clinical Outcomes of Coronavirus Disease 2019 in Chinese Patients with Autoimmune Diseases

Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience

The correlation between rituximab dose reduction and acute relapses of neuromyelitis optica spectrum disorder, lessons from COVID-19 epidemic

Impact of Immunomodulatory Therapy on COVID-19 Vaccine Response in Patients with Autoimmune Inflammatory Rheumatic Diseases

Impact of different classes of immune-modulating treatments on B cell-related and T cell-related immune response before and after COVID-19 booster vaccination in patients with immune-mediated diseases and primary immunodeficiency: a cohort study

COVID-19 prophylaxis, diagnostics, and treatment in patients with rheumatic diseases. The Polish experts panel opinion

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Covid-19 Vaccine Failure in A Patient on Rituximab Therapy

Application of biological medicinal products and tyrosine kinase inhibitors in rheumatoid arthritis and COVID-19: A systematic review of scientific literature

The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence

SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases

Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases

Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac

Autoimmune rheumatic diseases and COVID-19 vaccination: a retrospective cross-sectional study from Astana

COVID-19 outcomes in patients with and without autoimmune rheumatic diseases: A multicenter comparative study

T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis

Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients With Inflammatory Rheumatic Diseases in Portugal—A Multicenter, Nationwide Study

Clinical features of patients with rheumatic and musculoskeletal diseases during the coronavirus disease 2019 pandemic and the association of its relapse with infection: Across‐sectional study